Primary tumor cells derived from three HER2-negative exemplary breast cancer patients were treated with combinations of agonists and inhibitors for HER1 (Erlotinib; 500 nM), HER2 (Tucatinib; 250 nM), or c-Met (Tepotinib; 50 nM). Here, ERBB2 is linked to breast cancer.